Lerisetron

Lerisetron
Systematic (IUPAC) name
	1-benzyl-2-piperazin-1-yl-1H-benzimidazole
Identifiers
CAS Number	143257-98-1
ATC code	none
PubChem	CID: 65997
ChemSpider	59389
UNII	Q36R82SXRG
ChEMBL	CHEMBL56900
Synonyms	Lerisetron
Chemical data
Formula	C18H20N4
Molecular mass	292.378 g/mol
	InChI InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2 ; Key:PWWDCRQZITYKDV-UHFFFAOYSA-N ;
(what is this?) (verify)

Lerisetron (F-0930-RS) is a drug which acts as an antagonist at the 5HT₃ receptor^[1] It is a potent antiemetic^[2]^[3] and is currently in clinical trials for the treatment of nausea associated with cancer chemotherapy.^[4]

References

↑ Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. 1997 Feb 14;40(4):586-93. PMID 9046349
↑ Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998;37(7-8):759-63. PMID 10050999
↑ Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittelforschung. 2002;52(9):689-94. PMID 12404884
↑ Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. 2003 Jul;4(7):874-7. PMID 14619411

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.